AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34600960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) combined with fluoxetine
Number of subjects: 0
Study 34600960 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine alone
Number of subjects: 0
Study 33893337 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 109
Study 33893337 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab
Number of subjects: 109
Study 33893337 — intervention group
Group type: COMPARATOR
Intervention: Higher neutrophil/Lymphocyte ratio
Number of subjects: 109
Study 33893337 — intervention group
Group type: COMPARATOR
Intervention: Lower PaO2/FiO2, 2 days after treatment
Number of subjects: 109
Study 36170988 — intervention group
Group type: EXPERIMENTAL
Intervention: safetxt intervention (text messages)
Number of subjects: 6248
Study 36170988 — intervention group
Group type: COMPARATOR
Intervention: Control (monthly text message)
Number of subjects: 6248
Study 33468208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mingjing granule as an add-on to intravitreous ranibizumab
Number of subjects: 180
Study 33468208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 180
Study 35612103 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven knowledge representation
Number of subjects: 0
Study 35612103 — intervention group
Group type: COMPARATOR
Intervention: Existing terminologies
Number of subjects: 0
Study 33950082 — intervention group
Group type: COMPARATOR
Intervention: Control group (flat archwires progressively to 0.016x0.022‐in stainless‐steel)
Number of subjects: 30
Study 33950082 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (0.014‐in‐superelastic NiTi with mild accentuated COS for aligning, then 0.016x0.022‐in beta‐titanium accentuated COS archwires for leveling)
Number of subjects: 30
Study 36210358 — intervention group
Group type: EXPERIMENTAL
Intervention: Video augmented mirror therapy (MTVADG)
Number of subjects: 36
Study 36210358 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional mirror therapy (TMTG)
Number of subjects: 36
Study 36210358 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study 34371893 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavonoid foods added to daily diet
Number of subjects: 41
Study 35239783 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF, 5 mg/kg)
Number of subjects: 9
Study 35239783 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA, cellulose)
Number of subjects: 9
Study 32801255 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (Hb <7 g/dl)
Number of subjects: 224
Study 32801255 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (Hb <8 g/dl)
Number of subjects: 224
Study 32801255 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 224
Study 32801255 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 224
Study 33185650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat titrated to 10 mg daily
Number of subjects: 5050
Study 33185650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study 33185650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050
Study 32608933 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable rotational flywheel training
Number of subjects: 24
Study 32608933 — intervention group
Group type: COMPARATOR
Intervention: Standard rotational flywheel training
Number of subjects: 24
Study 36283068 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane application with universal adhesives (Scotchbond Universal, All‐Bond Universal, G‐Premio Bond, Clearfil SE Bond)
Number of subjects: 80
Study 36283068 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo-polymerization of universal adhesives
Number of subjects: 80
Study 34845786 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic villus sampling (CVS)
Number of subjects: 8581
Study 34845786 — intervention group
Group type: COMPARATOR
Intervention: Non-CVS
Number of subjects: 8581
Study 34845786 — intervention group
Group type: COMPARATOR
Intervention: Matched non-CVS
Number of subjects: 8581
Study 35688593 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTforIBD programme (8-week intervention with 1-hour sessions, including 3 one-to-one sessions with a psychologist and self-directed online sessions)
Number of subjects: 50
Study 35688593 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 50
Study 33839938 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model based on images
Number of subjects: 601
Study 33839938 — intervention group
Group type: COMPARATOR
Intervention: Radiomics model
Number of subjects: 601
Study 33839938 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning combined with clinical parameters (DLC) model
Number of subjects: 601
Study 33839938 — intervention group
Group type: EXPERIMENTAL
Intervention: DLC models for MVI-grade stratification
Number of subjects: 601
Study 33839938 — intervention group
Group type: EXPERIMENTAL
Intervention: DLC-predicted MVI status
Number of subjects: 601
Study 33839938 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy with wide resection margin
Number of subjects: 601
Study 33136237 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV-based gene therapy (e.g., Luxturna® - voretigene neparvovec‐rzyl)
Number of subjects: 0
Study 33136237 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV-based therapies
Number of subjects: 0
Study 35331719 — intervention group
Group type: COMPARATOR
Intervention: MET‐only
Number of subjects: 75
Study 35331719 — intervention group
Group type: COMPARATOR
Intervention: MET+STM
Number of subjects: 75
Study 33180609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasojejunal (NJ) tube feeding
Number of subjects: 40
Study 33180609 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric (NG) tube feeding
Number of subjects: 40
Study 32683635 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutations
Number of subjects: 938
Study 32683635 — intervention group
Group type: EXPERIMENTAL
Intervention: Exon 4 KRAS mutations
Number of subjects: 938
Study 32683635 — intervention group
Group type: EXPERIMENTAL
Intervention: Exon 2 KRAS mutations
Number of subjects: 938
Study 32683635 — intervention group
Group type: EXPERIMENTAL
Intervention: Exon 3 KRAS mutations
Number of subjects: 938
Study 32683635 — intervention group
Group type: EXPERIMENTAL
Intervention: NRAS mutations
Number of subjects: 938
Study 33736584 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal positive end-expiratory pressure (n = 28)
Number of subjects: 57
Study 33736584 — intervention group
Group type: COMPARATOR
Intervention: Control (fixed positive end-expiratory pressure, 5 cm H₂O; n = 29)
Number of subjects: 57
Study 32586939 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole plus bevacizumab
Number of subjects: 294
Study 32586939 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 294
Study 32586939 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC-positive patients
Number of subjects: 294
Study 32586939 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure to clear CTCs during treatment
Number of subjects: 294
Study 34957321 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation scenario of unconscious person with physiological breathing (15/min)
Number of subjects: 102
Study 34957321 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation scenario of gasping (<10/min)
Number of subjects: 102
Study 34957321 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation scenario of apnea (resuscitation dummy AmbuMan® Wireless)
Number of subjects: 102
Study 34957321 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of preparedness for resuscitation situations
Number of subjects: 102
Study 35643841 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 0
Study 35643841 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin use
Number of subjects: 0
Study 34024696 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial Release (MFR)
Number of subjects: 24
Study 34024696 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 24
Study 32569172 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral balloon kyphoplasty (BKP)
Number of subjects: 150
Study 32569172 — intervention group
Group type: COMPARATOR
Intervention: Bilateral balloon kyphoplasty (BKP)
Number of subjects: 150
Study 36240214 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Management Review (MMR) service
Number of subjects: 106
Study 36240214 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MMR service)
Number of subjects: 106
Study 34611236 — intervention group
Group type: EXPERIMENTAL
Intervention: Real direct current stimulation
Number of subjects: 14
Study 34611236 — intervention group
Group type: COMPARATOR
Intervention: Sham direct current stimulation
Number of subjects: 14
Study 32379581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PRP injection into pathological shoulder tendons targeting the supraspinatus
Number of subjects: 6
Study 33720418 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 2377
Study 33720418 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9,204 for APT, n = 9,196 for ARS, n = 8,788 for AOM)
Number of subjects: 2377
Study 33720418 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2377
Study 32690791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR) 600 mg infusions every 24 weeks
Number of subjects: 0
Study 32690791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 0
Study 32690791 — intervention group
Group type: COMPARATOR
Intervention: Interferon (IFN)‐β‐1a (44 μg 3 times weekly)
Number of subjects: 0
Study 35232596 — intervention group
Group type: EXPERIMENTAL
Intervention: liq PCV-free HRV
Number of subjects: 1351
Study 35232596 — intervention group
Group type: COMPARATOR
Intervention: lyo HRV
Number of subjects: 1351
Study 32427108 — intervention group
Group type: EXPERIMENTAL
Intervention: iCAN-DO intervention (Step 1: access to psychoeducational material and peer support; Step 2: internet-based cognitive behavioral therapy)
Number of subjects: 15
Study 36007555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low contrast percutaneous coronary intervention (ULC-PCI)
Number of subjects: 82
Study 36007555 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI
Number of subjects: 82
Study 32714133 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS)
Number of subjects: 30
Study 32714133 — intervention group
Group type: COMPARATOR
Intervention: Regular therapies
Number of subjects: 30
Study 32714133 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS
Number of subjects: 30
Study 35189420 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-tailored 3D-printing models
Number of subjects: 36
Study 35189420 — intervention group
Group type: COMPARATOR
Intervention: Control group (no case-tailored model)
Number of subjects: 36
Study 32640112 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical drainage with combined strategies
Number of subjects: 169
Study 32640112 — intervention group
Group type: COMPARATOR
Intervention: Sphincter-sparing surgeries or seton removal
Number of subjects: 169
Study 32640112 — intervention group
Group type: COMPARATOR
Intervention: Fistulotomy
Number of subjects: 169
Study 32640112 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressants
Number of subjects: 169
Study 32640112 — intervention group
Group type: COMPARATOR
Intervention: Anterior fistula
Number of subjects: 169
Study 32640112 — intervention group
Group type: COMPARATOR
Intervention: Supralevator extension
Number of subjects: 169
Study 34673535 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention using the SaltSwap app with individualized advice from a health care professional
Number of subjects: 47
Study 34673535 — intervention group
Group type: COMPARATOR
Intervention: Advice leaflet (control)
Number of subjects: 47
Study 32544572 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice (90-min classes, 2 times per week for 10 weeks)
Number of subjects: 33
Study 32544572 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice
Number of subjects: 33
Study 32544572 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 32544572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 35584600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis during bronchoscopy
Number of subjects: 60
Study 35584600 — intervention group
Group type: COMPARATOR
Intervention: Standard bronchoscopy
Number of subjects: 60
Study 34814074 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning methods (role-play simulations)
Number of subjects: 94
Study 34814074 — intervention group
Group type: COMPARATOR
Intervention: Passive learning methods (lecture)
Number of subjects: 94
Study 34791350 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 fractional doses of IPV (fIPV-0.1mL, intradermal) at age 6 and 14 weeks
Number of subjects: 799
Study 34791350 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 fractional doses of IPV (fIPV-0.1mL, intradermal) at age 10 and 14 weeks
Number of subjects: 799
Study 34791350 — intervention group
Group type: COMPARATOR
Intervention: 1 full dose of IPV (0.5mL, intramuscular) at age 14 weeks
Number of subjects: 799
Study 32744906 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 1682
Study 32744906 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids with acupuncture
Number of subjects: 1682
Study 32744906 — intervention group
Group type: COMPARATOR
Intervention: OA nonacupuncture cohort
Number of subjects: 1682
Study 32744906 — intervention group
Group type: COMPARATOR
Intervention: Non-OA cohort
Number of subjects: 1682
Study 32564093 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral micronized progesterone at bedtime
Number of subjects: 60
Study 32564093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32564093 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational data
Number of subjects: 60
Study 35202010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 48
Study 35202010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33277768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aetiological testing using Xpert® CT/NG and Xpert® TV assays
Number of subjects: 841
Study 33277768 — intervention group
Group type: COMPARATOR
Intervention: Syndromic management
Number of subjects: 841
Study 33277768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aetiological testing
Number of subjects: 841
Study 35033346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation, 60 g of product containing 30 g of FO daily
Number of subjects: 30
Study 35033346 — intervention group
Group type: COMPARATOR
Intervention: Canola oil (CO) supplementation, 30 mL daily
Number of subjects: 30
Study 35033346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 30
Study 34925649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (1.25 mg/d)
Number of subjects: 64
Study 34925649 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg/d)
Number of subjects: 64
Study 34925649 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional therapy only)
Number of subjects: 64
Study 34565193 — intervention group
Group type: EXPERIMENTAL
Intervention: CancerHelp-Talking Touchscreen (CancerHelp-TT)
Number of subjects: 129
Study 34565193 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 129
Study 32192465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 30
Study 32192465 — intervention group
Group type: COMPARATOR
Intervention: Standard wound closure
Number of subjects: 30
Study 35960047 — intervention group
Group type: EXPERIMENTAL
Intervention: QFPD-LHQW
Number of subjects: 318
Study 35960047 — intervention group
Group type: COMPARATOR
Intervention: QFPD
Number of subjects: 318
Study 35960047 — intervention group
Group type: COMPARATOR
Intervention: LHQW
Number of subjects: 318
Study 33432439 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin for 3 months
Number of subjects: 30
Study 33432439 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 30
Study 33323306 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (2 mA current, 20 minutes per session, repeated once daily for 5 consecutive days)
Number of subjects: 54
Study 33323306 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (30 seconds stimulation, 20 minutes no current)
Number of subjects: 54
Study 33323306 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received acetaminophen
Number of subjects: 54
Study 32074356 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% pilocarpine ophthalmic solution (two drops)
Number of subjects: 0
Study 32074356 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% pilocarpine ophthalmic solution (three drops)
Number of subjects: 0
Study 32296971 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC)
Number of subjects: 623
Study 32095922 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs) applied to the maxillary molar region (n=10)
Number of subjects: 20
Study 32095922 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 20
Study 32095922 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral side of the experimental group (n=10)
Number of subjects: 20
Study 32095922 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Number of subjects: 20
Study 32095922 — intervention group
Group type: COMPARATOR
Intervention: Control group and experimental group (contralateral side)
Number of subjects: 20
Study 35994437 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychotherapy
Number of subjects: 236
Study 35994437 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychotherapy
Number of subjects: 236
Study 32404782 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted quadrivalent influenza vaccine (aIIV4)
Number of subjects: 10644
Study 32404782 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted comparator influenza vaccine
Number of subjects: 10644
Study 33536049 — intervention group
Group type: COMPARATOR
Intervention: ctDNA methylation markers in early detection of CRC (training set)
Number of subjects: 742
Study 33536049 — intervention group
Group type: COMPARATOR
Intervention: ctDNA methylation markers in early detection of CRC (test set)
Number of subjects: 742
Study 33536049 — intervention group
Group type: COMPARATOR
Intervention: ctDNA methylation markers for stage I CRC
Number of subjects: 742
Study 33536049 — intervention group
Group type: COMPARATOR
Intervention: ctDNA methylation markers for stage II CRC
Number of subjects: 742
Study 33536049 — intervention group
Group type: COMPARATOR
Intervention: ctDNA methylation markers for stage III CRC
Number of subjects: 742
Study 33536049 — intervention group
Group type: COMPARATOR
Intervention: ctDNA methylation markers for stage IV CRC
Number of subjects: 742
Study 33536049 — intervention group
Group type: COMPARATOR
Intervention: ctDNA methylation markers for stage I-III CRC (training set)
Number of subjects: 742
Study 33536049 — intervention group
Group type: COMPARATOR
Intervention: ctDNA methylation markers for stage I-III CRC (test set)
Number of subjects: 742
Study 33536049 — intervention group
Group type: COMPARATOR
Intervention: ctDNA methylation markers compared to methylated SEPT9 model
Number of subjects: 742
Study 32819348 — intervention group
Group type: EXPERIMENTAL
Intervention: Shelter group (temporary housing residents)
Number of subjects: 1089
Study 32819348 — intervention group
Group type: COMPARATOR
Intervention: Community residents (non-disaster areas)
Number of subjects: 1089
Study 35170247 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate mouthwash
Number of subjects: 144
Study 35170247 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc chloride mouthwash
Number of subjects: 144
Study 35170247 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 144
Study 34387828 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal application for acupoints (HAA) group
Number of subjects: 121
Study 34387828 — intervention group
Group type: COMPARATOR
Intervention: Placebo application for acupoints (PAA) group
Number of subjects: 121
Study 35717169 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 2395
Study 35717169 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 2395
Study 33831504 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-based resilient denture liner (RD group)
Number of subjects: 0
Study 33831504 — intervention group
Group type: COMPARATOR
Intervention: Conventional denture base (CD group)
Number of subjects: 0
Study 33820576 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) 1 capsule containing 1×10^10 cells twice daily (n = 44)
Number of subjects: 88
Study 33820576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 88
Study 32196717 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 64
Study 32196717 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=45)
Number of subjects: 64
Study 32196717 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MPV
Number of subjects: 64
Study 32196717 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone
Number of subjects: 64
Study 36195995 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline hydration
Number of subjects: 65
Study 36195995 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 65
Study 36195995 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 65
Study 33481771 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxyindole (5-HI) administered orally in rats
Number of subjects: 0